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Received December 21, 2011; accepted April 16, 2012AbstractBackground: Endoscopic methods are currently the treatment of choice for patients with common bile duct (CBD) stones, but subsequent
management of the intact gallbladder for patients following endoscopic treatment is still controversial. The primary aim of this study was to
discover the association between gallbladder status and recurrent biliary complications for patients with CBD stones after endoscopic treatment.
Additionally, we also sought to determine risk factors for recurrent biliary complications in these patients.
Methods: The records of 1625 patients with CBD stones following endoscopic treatment were reviewed. A total of 681 patients were enrolled
and subsequently categorized into four groups: Group 1 (n ¼ 201), calculous gallbladder; Group 2 (n ¼ 140), acalculous gallbladder; Group 3
(n ¼ 175), elective cholecystectomy after endoscopic treatment; and Group 4 (n ¼ 165), prior cholecystectomy. The basic demographics and
recurrent biliary complications during follow-up among these four groups were analyzed by Chi-square test, ANOVA, Kaplan-Meier analysis,
and log-rank test.
Results: During the median follow-up period of 34 months, 133 patients (20%) with recurrent biliary complications were identified. The
recurrence rates of Groups 1, 2, 3, and 4 were 29%, 11%, 15%, and 19%, respectively. Kaplan-Meier analysis showed that patients with
calculous gallbladder had a significantly higher rate of recurrent biliary complication. In multivariate analysis, patients with a history of
cirrhosis, juxta-papillary diverticulum, calculous gallbladder, CBD size 1.5 cm, and endoscopic management with endoscopic sphincterotomy
were at a higher risk for developing biliary complications ( p ¼ 0.029, p ¼ 0.039, p < 0.001, p ¼ 0.002, p ¼ 0.021, respectively.)
Conclusion: Patients with cholecystolithiasis and CBD stones had a higher incidence of recurrent biliary complications. For some of these
patients, elective cholecystectomy following endoscopic treatment may be considered. However, routine elective cholecystectomy in patients
with normal gallbladder is not appropriate because of the low recurrence of biliary complications. Whether gallbladder function affects the
biliary clearance and biliary complications requires further research.
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Endoscopic management of common bile duct (CBD)
stones, including endoscopic sphincterotomy (ES) and endo-
scopic balloon dilation (EBD), is a common and widespreadhinese Medical Association. All rights reserved.
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arising from endoscopic management varies from 4% to 24%.1
Dilated bile duct, juxtapapillary diverticulum (JPD), brown
pigmented stones, lithotripsy during treatment, pneumobilia
after ES, and calculous gallbladder in situ have all been
proposed as possible risk factors for recurrent biliary
complications,2 but such risk factors can vary from study to
study, and between different populations.
Although some studies reported that an intact calculous
gallbladder is a risk factor for recurrent biliary complications,
patient with an acalculous gallbladder may still develop
similar complications.3e5 In some Asian studies, routine
cholecystectomy following ES does not reduce the incidence
of recurrent biliary complications.6e8 However, 15% to 37%
of patients after ES whose gallbladder is left in situ will
develop symptoms requiring cholecystectomy during a follow-
up period ranging from 17 months to over 5 years.9e12
Therefore, in some reports, cholecystectomy is recom-
mended after bile duct clearance in patients with a calculous
gallbladder.9,11,13 The management of patients having acal-
culous gallbladder after bile duct clearance remains contro-
versial. In one Asian study, patients with an acalculous
gallbladder subsequent to initial clearance of the bile duct had
a lower rate of recurrence of bile duct stones.14
Unlike patients from western countries, the major compo-
nent of common bile duct stones in Chinese patients is bilir-
ubinate. Therefore, the role of gallbladder status in recurrent
biliary complications may differ.12,15,16
The aim of this retrospective study was to find the rela-
tionship between different gallbladder statuses and recurrent
biliary complications for patients with CBD stones following
endoscopic treatment, and also to evaluate whether elective
cholecystectomy can effectively reduce biliary complications.
2. Methods2.1. PatientsWe enrolled 1625 consecutive patients admitted to Kaoh-
siung Veterans General Hospital from January 1991 to
December 2008 with CBD stones, who received either ES or
EBD and successful clearance of the bile duct stones. Patients
with concomitant malignancies, prior Billroth II gastrectomy,
incomplete clearance of bile duct and a follow-up period of
<6 months were excluded. Consequently, a total of 681
patients were included in this study. These patients were
categorized into four groups according to the gallbladder
status: Group 1, intact gallbladder with stones; Group 2, intact
gallbladder without stones; Group 3, elective cholecystectomy
following endoscopic treatment; and Group 4, cholecystec-
tomy before endoscopic treatment.2.2. ProceduresStandard endoscopic treatment was performed using a side-
viewed endoscope (JF1T-20, JF-240, JF1T-30; Olympus
Optical Corporation, Tokyo, Japan). The stone number, stonesize (the largest diameter), and the CBD size were measured
by endoscopic retrograde cholangiography. For ES, sphinc-
terotomy was done using a wire-guided sphincterotome
(Olympus Optical Corporation). For EBD, a dilated
balloon catheter (Olbert, 8 mm and 10 mm in diameter and
4 cm in length; CRE, 6e8 mm, 8e10 mm, 10e12 mm,
12e15 mm, 15e18 mm, 18e20 mm in diameter and 5.5 cm in
length; Microvasive, Boston Scientific Corporation, Water-
town, MA, USA) was passed over the guide wire into the bile
duct after guidewire insertion as ES. The size of the balloon
was determined by the stone size and did not exceed the
maximum diameter of the CBD. The balloon was gradually
inflated with sterile saline at a pressure according to the
manufacturer’s instructions, and balloon inflation was halted
whenever the patient experienced discomfort. The stones in
the common bile duct were then removed using a Dormia
basket after ES or EBD, with or without use of a mechanical
lithotriptor (BML-4Q; Olympus Optical). If the first treatment
resulted in incomplete removal of all stones, a second stone
extraction attempt was performed within 7 days. All patients
were observed in the hospital for at least 24 hours following
endoscopic treatment.2.3. Follow-upDuring endoscopic treatment, the general data and the
endoscopic findings, including the presence of JPD, stone size,
and stone numbers, were recorded. Stone removal was
declared complete if the final cholangiogram showed no
residual stones. After clearance of the bile duct and normali-
zation of liver function, each patient was routinely advised to
have regular follow-up evaluations that included an interview,
biochemical testing of liver function (total serum bilirubin,
albumin, alanine aminotransferase, aspartate aminotransferase,
and alkaline phosphatase), and transabdominal ultrasonog-
raphy (US) every 3 to 6 months. Follow-up for patients with an
intact gallbladder occurred every 3 months, and patients
having previous cholecystectomy before endoscopic treatment
or elective cholecystectomy after endoscopic treatment were
followed up every 6 months. If any biliary symptoms devel-
oped between visits, the patient was advised to contact us
immediately. Endoscopic retrograde cholangiography was
performed if US demonstrated echogenic foci within the bile
duct or significant dilatation of the common bile duct in
comparison with previous US, or if abnormal liver function
tests developed accompanied by typical biliary pain.
All complicating biliary events that occurred during follow-
up were recorded, including acute cholecystitis, cholangitis,
biliary colic, recurrent CBD stones, and acute pancreatitis.2.4. Statistical analysisAll statistical analyses were performed with the SPSS
program (version 12.0.1C; SPSS Inc., Chicago, USA). The
values were expressed as mean  SD. Categorical variables
were tested by the Chi-square test or Fisher’s exact test. The
continuous values between four categorical groups were
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considered significant. The cumulative biliary complication
rates between the four groups were calculated by the Kaplan-
Meier method. We used binary logistic regression for multi-
variate analysis of the risk factors.
3. Results
The 681 patients in this study were categorized into four
groups according to the gallbladder status: Group 1 (n ¼ 201),
intact gallbladder with stones; Group 2 (n ¼ 140), intact
gallbladder without stones; Group 3 (n ¼ 175), elective
cholecystectomy following endoscopic treatment; and Group 4
(n ¼ 165), cholecystectomy before endoscopic treatment. The
characteristics of the four groups of patients were shown in
Table 1. The median follow-up time was 34 months (6e212
months); 68% of all patients were male, 49% of them had
a JPD, and 6% were receiving lithotripsy. The mean age was
66  14 years, mean CBD size 1.5  0.5 cm, and mean stone
size 1.1  0.5 cm, with 43% of patients having multiple
CBDS. There were no significant difference between the four
groups in gender, JPD, cirrhosis, total bilirubin level, and the
number of stones. We found that patients with prior chole-
cystectomy on average had a larger stone size (1.3  0.6 cm,
p ¼ 0.004), a larger CBD size (1.7  0.6 cm, p < 0.001), and
were more likely to receive lithotripsy (11%, p ¼ 0.018).
Patients receiving elective cholecystectomy were younger than
the other three groups (62  15 year-old, p < 0.001).
The interval between endoscopic management and the
cholecystectomy was a median of 6 days (1e300). Five
patients had the cholecystectomy with an interval of >100
days, three had no recurrent biliary complications, and two
had recurrent biliary complications, but the complications all
occurred at least 6 months after the surgery.
In total, 133 (20%) biliary complications occurred during
the follow-up period. Within the four groups, there were 29%
(59/201) of patients in Group 1, 11% (16/140) in Group 2,
15% (26/175) in Group 3, and 19% (32/165) in Group 4 who
had biliary complications in the follow-up period ( p < 0.001).
Those biliary complications included recurrent bile duct stoneTable 1
Characteristics of the four groups of patients following endoscopic treatment for c
Group 1 Group 2
n 201 140
Male gender 66% 74%





Lithotripsy (%) 4% 4%
Stone size (cm) 1.1  0.47 1.2  0.57
Multiple stones 46% 42%
CBD size (cm) 1.5  0.51 1.5  0.48
Total bilirubin (mg/dL) 4.4  4.34 4.3  4.09
Follow-up time (months) 33.3  31.28 47.8  40.97
CBD ¼ common bile duct; DM ¼ diabetes mellitus; JPD ¼ juxtapapillary divertievents in 31, 14, 24, and 26 patients in Groups 1, 2, 3, and 4,
respectively; 16 acute cholecystitis events occurred in Group 1
patients; biliary colic events occurred in 11, one, two, and
three patients of Groups 1, 2, 3, and 4, respectively; and acute
pancreatitis occurred in one patient in Group 4 (Table 2). All
16 patients with acute cholecystitis received surgical resection.
Three of the Group 1 patients with acute cholecystitis devel-
oped gallbladder rupture. One patient died after the operation,
and the other 15 patients with acute cholecystitis recovered
after surgery. Gallbladder cancer was not observed in these
patients. All patients with recurrent bile duct stones were
successfully treated with repeated ERCP and stone extraction.
Those patients with cholangitis were treated conservatively
with antibiotics and the image studies revealed no recurrent
bile duct stones. In patients with typical biliary colic, the liver
biochemical data was normal, which included total serum
bilirubin, albumin, alanine aminotransferase, aspartate
aminotransferase, and alkaline phosphatase. Only one patient
(who had a history of prior cholecystectomy) developed acute
pancreatitis, and repeated ERCP did not demonstrate any bile
duct stones. He was treated successfully with conservative
medical management.
Kaplan-Meier analysis was performed to compare the
incidence of recurrent biliary complication between the four
groups. It revealed a significantly higher incidence of biliary
complications in Group 1 compared to the other three groups
( p < 0.001) (Fig. 1).
Among the potential risk factors for the occurrence of
biliary complications, there were six significant factors
(Table 3) noted in univariate analysis: history of cirrhosis,
JPD, calculous gallbladder, use of lithotriptor for stone
clearance, CBD size 1.5 cm, and endoscopic management
with ES patients.
In multivariate analysis, patients with a history of cirrhosis,
JPD, calculous gallbladder, CBD size 1.5 cm, and endo-
scopic management with ES were at a higher risk for devel-
oping biliary complications ( p ¼ 0.029, p ¼ 0.039, p < 0.001,
p ¼ 0.002, p ¼ 0.021 respectively, Table 4).
Patients with CBD stones managed with ES had a higher
risk of biliary complications compared to the EBD groupommon bile duct stones.
Group 3 Group 4 All p
175 165 681
65% 70% 68% 0.278
62.3  14.76 67.2  11.99 65.8  13.62 <0.001
43% 55% 49% 0.151
17% 12% 16% 0.148
29% 22% 30% 0.060
4% 8% 7% 0.446
4% 11% 6% 0.018
1.0  0.52 1.3  0.56 1.1  0.53 0.004
42% 43% 43% 0.808
1.4  0.48 1.7  0.56 1.5  0.52 <0.001
4.4  3.89 3.3  2.81 4.2  3.90 0.088
52.2  42.95 50.2  42.44 45.3  39.95 <0.001
culum.
Table 2
Recurrent biliary complications in 4 groups of patients.
Total n ¼ 681 Group 1 n ¼ 201 Group 2 n ¼ 140 Group 3 n ¼ 175 Group 4 n ¼ 165
Recurrent CBDS 95 31 (15%) 14 (10%) 24 (14%) 26 (16%)
Acute cholecystitis 16 16 0 0 0
Biliary colic 17 11 1 2 3
Cholangitis 4 1 1 0 2
Acute pancreatitis 1 0 0 0 1
Total 133 (20%) 59 (29%)* 16 (11%) 26 (15%) 32 (19%)
*p < 0.001 compared with other three groups (1 vs. 2, 1 vs. 3, 1 vs. 4) by log-rank test. CBDS ¼ common bile duct stones.
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two different treatment modalities were further analyzed
according to gallbladder status (Table 5). Only patients with
a calculous gallbladder (Group 1) receiving ES had a signifi-
cantly higher percentage of biliary complication compared to
patients receiving EBD (35.5% vs 19.7%, p ¼ 0.018). The
other three groups showed no statistical difference between ES
and EBD. Group 1 patients were further analyzed to see which
complication was associated with endoscopic management.
Patients in Group 1 with EBD had a reduced CBD stone
recurrence rate and a lower incidence of biliary colic
compared to ES (Table 6).
4. Discussion
This study demonstrated a higher incidence of recurrent
biliary complications in patients with a calculous gallbladder
(up to 29%) than in other patients. Although the recurrence of
CBDS in patients with a calculous gallbladder did not
significantly differ from other patients, 8% of patients devel-
oped acute choleycystitis during the follow-up period, and one
of them died of sepsis. Ando et al14 reported that 11% of
patients after ES with calculous gallbladder and 2% of patientsFig. 1. The cumulative incidences of biliarywith elective cholecystectomy had recurrent bile duct stones.
In a Dutch study,11 47% of those patients with calculous
gallbladder developed recurrent biliary events and 37%
required a cholecystectomy. In a Chinese study,13 elective
cholecystectomy following endoscopic treatment of bile duct
stones reduced recurrent biliary events (by 24% in those with
gallbladder in situ vs. 7% in those receiving laparoscopic
cholecystectomy), so routine cholecystectomy is advisable for
those patients with a calculous gallbladder after clearance of
the bile duct.
Most of our patients, particularly elderly patients, were
unwilling to undergo an operation for symptom relief after
endoscopic management; this might be attributable to cultural
differences. In our basic patient demographic data, we found
patients receiving elective cholecystectomy were younger than
in other groups (Table 1). The morbidity rate of cholecystec-
tomy was higher in elderly patients, and even patients with
elective cholecystectomy still had recurrent CBD stones.7 The
decision of whether to perform cholecystectomy must also
consider the surgical risk to the patients.1 In those patients
with higher operational risk, and those unwilling to receive
elective cholecystectomy, close monitoring during follow-up
is indicated to avoid lethal complications.17complications in 4 groups of patients.
Table 4
Multivariate analysis of the risk factors for recurrent biliary complications.
OR 95% CI p
Cirrhosis 2.143 1.083e4.239 0.029
JPD 1.530 1.022e2.290 0.039
Gallbladder stone 2.684 1.773e4.065 <0.001
CBD size 1.5 cm 1.943 1.264e2.987 0.002
Lithotripsy 1.848 0.883e3.867 0.103
ES 1.779 1.091e2.902 0.021
CBD ¼ common bile duct; CI ¼ confidence interval; ES ¼ endoscopic
sphincterotomy; JPD ¼ juxtapapillary diverticulum; OR ¼ odds ratio.
Table 5
Recurrence of biliary symptoms between two methods of endoscopic managemen
Group 1 Group 2 G
ES 35.5% (44/124) 12.5% (13/104) 1
EBD 19.7% (15/76) 6.3% (2/32) 5
p 0.018 0.520 0
CBD ¼ common bile duct; EBD ¼ endoscopic balloon dilation; ES ¼ endoscopic
Table 3
Univariate analysis of risk factors for recurrent biliary complications.
Recurrence (n) Nonrecurrence (n) p
Gender
Male 91 373 1.000
Female 42 175
Age
65 87 357 1.000
<65 46 191
Hypertension
Yes 44 159 0.398
No 89 389
Type 2 DM
Yes 18 90 0.508
No 115 458
Cirrhosis
Yes 15 30 0.030
No 118 518
JPD
Yes 76 256 0.034
No 57 292
Gallstone
Yes 59 142 0.000
No 74 406
Lithotripsy
Yes 13 27 0.040
No 120 521
Stone number
2 67 229 0.080
Single 66 319
Stone size
0.8 cm 106 401 0.350
<0.8 cm 25 120
CBD size
1.5 cm 92 286 <0.001
<1.5 cm 41 261
Endoscopic management
ES 103 369 0.013
EBD 27 172
CBD ¼ common bile duct; DM ¼ diabetes mellitus; EBD ¼ endoscopic
balloon dilation; ES ¼ endoscopic sphincterotomy; JPD ¼ juxtapapillary
diverticulum.
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patients after EBD, and found biliary complications were seen
in 12.4% of the cases. The recurrent biliary complications
were more frequent in the calculous gallbladder group than in
the acalculous gallbladder, elective cholecystectomy, and prior
cholecystectomy groups (22.6% vs. 9.2%, 2.8%, and 13.5%,
respectively); stone recurrence was seen in 15.6%, 5.9%,
2.4%, and 10.8%, respectively. Our study showed similar rates
of recurrent biliary complications of 29%, 11%, 15%, and
19%, and stone recurrence rates of 15%, 10%, 14%, and 16%
respectively. Unlike the Japanese study, our patients who
underwent elective cholecystectomy had a similar rate of
recurrent CBDS as the other groups.
Gallstones are primarily comprised of cholesterol and bile
pigments. In studies focusing on patients from western coun-
tries, gallbladder stones are mainly composed of cholesterol
(consisting of more than 50% cholesterol).18 However, in
Asian patients, most gallstones are pigmented stones.15 In
western countries, most of the common bile duct stones were
secondary, coming from the passage of gallstones in the
gallbladder, and primary CBD stones were seen less
frequently. In our previous study, bilirubinate was the
predominant composition of initial or recurrent CBD stone in
Chinese patients,15 so the role of the gallbladder in recurrent
CBDS differs from that role in populations where cholesterol
is the major gallstone component.
In the basic demographic data, we also found patients with
prior cholecystectomy before endoscopic treatment had larger
stones (1.3  0.6 cm, p ¼ 0.004), larger CBDs (1.7  0.6 cm,
p < 0.001), and a higher rate of undergoing lithotripsy (11%,
p ¼ 0.018). Gallbladder motility is important to deliver bile
through the CBD to the duodenum. It also helps to flush out
the newly produced stone particles and prevent new stone
formation in the bile duct.14 Patients with prior cholecystec-
tomy may develop bile stasis due to the absence of a “pump-
ing” effect of the gallbladder. These patients also lost their
gallbladder storage function, which resulted in larger CBD
size and more sizeable stone formation.
In the multivariate analysis, we found patients who had
cirrhosis, JPD, gallbladder stones in situ, CBD size >1.5 cm,
and those who underwent ES for CBD stone removal were at
risk of recurrent biliary complications. Most of those factors
have been mentioned in previous reports.2,4,7,14,16 In our study,
cirrhosis was a significant risk factor for recurrent biliary
symptoms, which was not mentioned in the previous literature.
There were 15 cirrhosis patients with recurrent biliary symp-
toms. Eleven of them had recurrent CBD stones, two had
biliary colic pain, and two had cholangitis. We know that
cirrhosis is the major risk factor for gallbladder stones witht for CBD stones.
roup 3 Group 4 Total
7.5% (21/120) 20.8% (25/120) 21.8% (103/472)




Recurrence of biliary complications between two methods of endoscopic management for CBD stones in Group 1 patients.
Recurrent CBDS Acute cholecystitis Biliary colic Cholangitis Acute pancreatitis Total
ES (n ¼ 124) 27 7 10 0 0 44
EBD (n ¼ 76) 4 9 1 1 0 15
p 0.002 0.117 0.042 0.38 0 0.018
CBD ¼ common bile duct; EBD ¼ endoscopic balloon dilation; ES ¼ endoscopic sphincterotomy.
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formation in cirrhosis patients might be due to several factors,
including reduced hepatic synthesis and transport of bile salts
and nonconjugated bilirubin,20 high estrogen levels,21 and
impaired gallbladder contraction in response to a meal.22
However, the reason for the recurrent CBD stone formation
in cirrhosis patients is unclear. In our study, the number of
cases in this subgroup was small, so it requires further large-
scale study for a more detailed evaluation.
In our previous study,23 we found that slower hepatic
clearance in quantitative cholescintigraphy is an important
factor for stone recurrence, and JPD is responsible for delayed
biliary emptying. JPD may also induce bacterial contamina-
tion in the bile of patients with a dysfunctional sphincter of
Oddi. These might contribute to the cause of the recurrent
biliary tract stone formation and biliary complications.
The dilated CBD is commonly contaminated with
bacteria1,24 and has delayed biliary emptying,23 which may
contribute to the pathogenesis of recurrent stones. Clearly,
small stone fragments after lithotriopsy may act as nidi,14
combined with biliary stasis in dilated bile duct, resulting in
recurrent stone formation.
Lithotripsy is a documented risk factor for recurrent biliary
complications,14 but it is not a significant factor in our study.
The reason might be that the stones in our patient were loose
in character, and we only had a small number of patients who
received lithotripsy.
Patients who underwent ES had significantly more recur-
rent biliary complications than those who underwent EBD
(22% vs 14% p ¼ 0.013) in this study, similar to results
Yasuda et al (25% vs 10%, p ¼ 0.0016).3 Unlike the traditional
EBD method (maximum inflated outer diameter of 8 mm,
dilating 1e2 minutes), we used the larger controlled radial
expansion balloon for dilation from 3 to 5 minutes.25 It has
a high success rate of stone clearance, fewer complications, it
minimizes the use of mechanical lithotripsy, and also has a low
stone recurrence rate of 10%.26 In our previous report, we
found 71.6% of patients had loss of the function of the
sphincter of Oddi following EBD.27 The patients after large
balloon EBD had less frequent recurrent biliary complication.
This was probably due to the fact that the distal bile duct and
whole biliary sphincter were dilated simultaneously, facili-
tating bile drainage and smooth passage of residual stone
fragments, or newly formed stone particles.
We subgrouped the patients into four different gallbladder
statuses to compare the difference between the patients
receiving ES or EBD. We found that patients with a calculous
gallbladder who received ES had a significantly higher
percentage of biliary complication compared to the patientsreceiving EBD (35.5% vs 19.7%, p ¼ 0.018), and that patients
with EBD had reduced recurrent CBD stones and bilairy colic
(of any statistical significance). In patients with a calculous
gallbladder, recurrent stones might be due to both primary and
secondary stones. Patients receiving EBD might have less
distal biliary stricture and the primary stone or secondary
stones may pass out more casually after the pumping effect of
the gallbladder, thus resulting in fewer biliary complications.
However, the exact mechanism of this process requires further
study to confirm.
There were some limitations to our study. Many patients
became symptom-free and did not return for follow-up
examinations, so only 42% of total patients were included in
this retrospective analysis. We may have underestimated or
overestimated the rate of biliary complications, especially the
rate of biliary colic. There is a wide variability of biliary
emptying in response to food in patients with CBDS following
endoscopic treatment.28 Therefore, further prospective studies
are required to examine the relationship between the intact
gallbladder function and recurrent biliary complications.Acknowledgments
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